It’s a bit of an extreme analogy, but some patients feel as though they’re dying of thirst, staring at water just out of reach. That feeling is particularly intense for those over 65 who rely heavily on advanced medical devices for their health, a situation compounded by current reimbursement policies from the Centers for Medicare Services.
In recent years, we’ve seen an exciting arrival of innovative medical devices aimed at treating various chronic illnesses, including glioblastoma, a severe type of brain cancer. These devices have transformed patient care, allowing many to receive essential treatment in the comfort of their own homes. While the Food and Drug Administration often recognizes these treatments by approving their use, the reimbursement policies from CMS can delay access for many patients who need them urgently.
Right now, there’s a significant gap—almost five years—between when a medical device gets FDA approval and when Medicare actually starts covering it. This period is particularly tough for cancer patients struggling with difficult diagnoses. Updating the reimbursement framework for these newly approved devices could enable patients to access life-changing treatments that not only enhance their quality of life but also allow them to connect more with loved ones.
Nobody can really prepare you for the devastating news of a brain tumor diagnosis. Yet, astonishingly, around 1.3 million Americans are facing this terrible reality every day.
Personally, during my own cancer journey, I had immense support from friends and family, which played a crucial role in my recovery. Their presence motivated me, and that experience pushed me to advocate for patients who deserve broad access to innovative treatments that could improve or even extend their lives.
Interestingly, there seems to be a shared understanding among leaders in Washington regarding the need to address this reimbursement gap. Previous attempts to rectify the issue, particularly under the last administration, aimed to provide transition coverage for emerging technologies, although results fell short of expectations. For instance, most devices did not receive expedited reviews, and there were limits placed on how many devices could be covered each year.
A group of bipartisan lawmakers is attempting to tackle this problem as well, proposing straightforward legislation to lift that five-device cap in the transition coverage and guarantee immediate Medicare coverage for all newly FDA-approved medical devices.
This initiative has garnered strong backing in both the House and the Senate, pushing towards a resolution that seems closer than before.
Fortunately, Senators Todd Young (R-Ind.) and Alex Padilla (D-Calif.) recently introduced a combined effort to streamline Medicare regulations aimed at improving access to innovative medical technologies. The proposed law, the Ensuring Patient Access to Critical Breakthrough Products Act, aims to enhance access to established treatments for seniors.
It’s disheartening that many elderly individuals find themselves waiting for coverage due to outdated Medicare policies that haven’t kept pace with medical advancements—not because effective treatments aren’t available.
Moving forward, it’s crucial for Congress to prioritize this legislation to eliminate barriers to innovative treatments deemed safe and effective by the FDA.
In the ongoing battle against cancer, all patients should have access to available treatments. Denying coverage for groundbreaking therapies effectively puts hope just out of reach.
